Document is current
Any future updates will be listed below
-
Authors
Feist, William N. https://orcid.org/0000-0002-5870-4460
Luna, Sofia E. https://orcid.org/0000-0002-9173-9518
Ben-Efraim, Kaya
Filsinger Interrante, Maria V.
Amorin, Alvaro https://orcid.org/0000-0002-3500-5085
Johnston, Nicole M.
Bruun, Theodora U. J.
Utz, Ashley https://orcid.org/0000-0003-2280-8521
Ghanim, Hana Y.
Lesch, Benjamin J.
McLaughlin, Theresa M.
Dudek, Amanda M. https://orcid.org/0000-0003-0239-3576
Porteus, Matthew H. https://orcid.org/0000-0002-3850-4648
-
Funding
Funding for this research was provided by:
The work was funded by the Sutardja Chuk Professorship for Definitive and Curative Medicine and the Laurie Kraus Lacob Fund for Pediatric Translational Research
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 19 March 2025
First Online: 1 April 2025
Competing interests
: M.H.P. serves on the scientific advisory board of Allogene Tx and is an advisor to Versant Ventures. M.H.P. has equity in CRISPR Tx and has equity and is a founder of Kamau Therapeutics. M.H.P., W.N.F., and S.E.L. are inventors on a provisional patent application submitted by The Board of Trustees of the Leland Stanford Junior University to the United States Patent and Trademark Office pertaining to the genetic engineering of cells for section of therapeutic antibodies (application number 63/561,249). The remaining authors declare no competing interests.
